Safety and Efficacy of Fecal Microbiota Transplant in Chronic Pouchitis-A Systematic Review With Meta-Analysis.

FMT Fecal Microbiota Transplant Pouchitis

Journal

Gastro hep advances
ISSN: 2772-5723
Titre abrégé: Gastro Hep Adv
Pays: Netherlands
ID NLM: 9918350485906676

Informations de publication

Date de publication:
2023
Historique:
received: 25 10 2022
accepted: 20 04 2023
medline: 25 4 2023
pubmed: 25 4 2023
entrez: 12 8 2024
Statut: epublish

Résumé

Pouchitis is the most common long-term complication after ileal-pouch anal anastomosis in patients with ulcerative colitis. We conducted a systematic review and meta-analysis evaluating the safety and efficacy of fecal microbiota transplant (FMT) in chronic antibiotic dependent and refractory pouchitis. Multiple databases were searched through April 2022 for studies that reported the efficacy and safety of FMT in patients with chronic pouchitis. Meta-analysis using random effects model was performed to calculate pooled rates. Eight studies with a total of 89 patients were included in our review, with 74 patients having received FMT and 15 patients having received placebo. The mean age ranged from 32.6 to 51.5 years. In patients that received FMT, the pooled rates of overall remission was (Pouchitis Disease Activity Index score < 7) 22% (95% CI, 9%-43%; I In patients with chronic pouchitis, FMT is safe though there are mixed results in terms of its long-term efficacy. Future Randomized Controlled Trials with larger sample sizes and greater standardization in terms of preparation, delivery, and length of treatment of FMT are needed to determine efficacy.

Sections du résumé

Background and Aims UNASSIGNED
Pouchitis is the most common long-term complication after ileal-pouch anal anastomosis in patients with ulcerative colitis. We conducted a systematic review and meta-analysis evaluating the safety and efficacy of fecal microbiota transplant (FMT) in chronic antibiotic dependent and refractory pouchitis.
Methods UNASSIGNED
Multiple databases were searched through April 2022 for studies that reported the efficacy and safety of FMT in patients with chronic pouchitis. Meta-analysis using random effects model was performed to calculate pooled rates.
Results UNASSIGNED
Eight studies with a total of 89 patients were included in our review, with 74 patients having received FMT and 15 patients having received placebo. The mean age ranged from 32.6 to 51.5 years. In patients that received FMT, the pooled rates of overall remission was (Pouchitis Disease Activity Index score < 7) 22% (95% CI, 9%-43%; I
Conclusion UNASSIGNED
In patients with chronic pouchitis, FMT is safe though there are mixed results in terms of its long-term efficacy. Future Randomized Controlled Trials with larger sample sizes and greater standardization in terms of preparation, delivery, and length of treatment of FMT are needed to determine efficacy.

Identifiants

pubmed: 39130120
doi: 10.1016/j.gastha.2023.04.005
pii: S2772-5723(23)00067-5
pmc: PMC11307912
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

843-852

Informations de copyright

© 2023 The Authors.

Auteurs

Tamara Kahan (T)

Division of Gastroenterology and Hepatology, NYU Grossman School of Medicine, New York, New York.

Saurabh Chandan (S)

Division of Gastroenterology and Hepatology, Creighton University School of Medicine, Omaha, Nebraska.

Shahab R Khan (SR)

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Smit Deliwala (S)

Division of Gastroenterology & Hepatology, Emory University, Atlanta, Georgia.

Shannon Chang (S)

Division of Gastroenterology and Hepatology, NYU Grossman School of Medicine, New York, New York.

Jordan Axelrad (J)

Division of Gastroenterology and Hepatology, NYU Grossman School of Medicine, New York, New York.

Aasma Shaukat (A)

Division of Gastroenterology and Hepatology, NYU Grossman School of Medicine, New York, New York.

Classifications MeSH